Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation

Eri Takematsu, Miles Massidda, Jeff Auster, Po Chih Chen, Byung Gee Im, Sanjana Srinath, Sophia Canga, Aditya Singh, Marjan Majid, Michael Sherman, Andrew Dunn, Annette Graham, Patricia Martin, Aaron B. Baker

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Stem cell factor (SCF) is a cytokine that regulates hematopoiesis and other biological processes. While clinical treatments using SCF would be highly beneficial, these have been limited by toxicity related to mast cell activation. Transmembrane SCF (tmSCF) has differential activity from soluble SCF and has not been explored as a therapeutic agent. We created novel therapeutics using tmSCF embedded in proteoliposomes or lipid nanodiscs. Mouse models of anaphylaxis and ischemia revealed the tmSCF-based therapies did not activate mast cells and improved the revascularization in the ischemic hind limb. Proteoliposomal tmSCF preferentially acted on endothelial cells to induce angiogenesis while tmSCF nanodiscs had greater activity in inducing stem cell mobilization and recruitment to the site of injury. The type of lipid nanocarrier used altered the relative cellular uptake pathways and signaling in a cell type dependent manner. Overall, we found that tmSCF-based therapies can provide therapeutic benefits without off target effects.

Original languageEnglish (US)
Article number2497
JournalNature communications
Issue number1
StatePublished - Dec 2022
Externally publishedYes

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General Physics and Astronomy


Dive into the research topics of 'Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation'. Together they form a unique fingerprint.

Cite this